Literature DB >> 9895080

The safety and effectiveness of remifentanil as an adjunct sedative for regional anesthesia.

M Lauwers1, F Camu, H Breivik, A Hagelberg, M Rosen, R Sneyd, A Horn, D Noronha, S Shaikh.   

Abstract

UNLABELLED: We assessed the sedative potential of continuous infusions of remifentanil with a validated composite alertness scale in 160 patients (ASA physical status I or II) undergoing hip replacement surgery with spinal block (n = 61) or hand surgery using brachial plexus block (n = 93). They were randomized to receive one of the following initial dose regimens in double-blinded fashion: placebo or 0.04, 0.07, or 0.1 microg x kg(-1) x min(-1) remifentanil subsequently titrated to effect. Additional midazolam IV was allowed for adequate sedation as required. The combined analysis of both surgery groups revealed a dose-related increase in achievement of sedation level > or =2 within 15 min of the start of the study drug infusion; all remifentanil dose comparisons with placebo reached significance (P < 0.001). The remifentanil 50% effective dose for a composite sedation level > or =2 within 15 min of the start of drug infusion was estimated as 0.043 microg x kg(-1) x min(-1) (95% confidence interval 0.01, 0.059). The requirement for midazolam decreased with increasing remifentanil dose compared with placebo (P < 0.001). The median time to return to alertness after the end of infusion was 10-12 min in the remifentanil groups and 5 min in the placebo group. Significant incidences of nausea, pruritus, sweating, and respiratory depression were reported during remifentanil infusions compared with placebo. The data suggest that remifentanil may be useful for supplementation of regional anesthesia, provided that ventilation is carefully monitored. IMPLICATIONS: In this dose-finding, placebo-controlled study, remifentanil infusions were used to provide sedation during spinal and brachial plexus regional anesthesia. The 50% effective dose for achievement of sedation was 0.043 microg x kg(-1) x min(-1). Return to alertness occurred after 10-12 min (median time). Remifentanil infusions can be used to supplement regional anesthesia, but this requires careful monitoring of ventilation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9895080     DOI: 10.1097/00000539-199901000-00025

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  Remifentanil Target-Controlled Infusion for Conscious Sedation in Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA): A Case Series.

Authors:  Simone Scarlata; Fabio Costa; Giuseppe Pascarella; Alessandro Strumia; Raffaele Antonelli Incalzi; Felice E Agrò
Journal:  Clin Drug Investig       Date:  2020-10       Impact factor: 2.859

Review 2.  Developments in procedural sedation for adults.

Authors:  J R Sneyd
Journal:  BJA Educ       Date:  2022-04-20

3.  Remifentanil compared with midazolam and pethidine sedation during colonoscopy: a prospective, randomized study.

Authors:  Maria M Manolaraki; Angeliki Theodoropoulou; Charalampos Stroumpos; Emmanouil Vardas; Pantelis Oustamanolakis; Aliki Gritzali; Gregorios Chlouverakis; Gregorios A Paspatis
Journal:  Dig Dis Sci       Date:  2007-05-03       Impact factor: 3.199

4.  Anesthesia drugs in the obstetric and gynecologic practice.

Authors:  Roulhac D Toledano; Bhavani-Shankar Kodali; William R Camann
Journal:  Rev Obstet Gynecol       Date:  2009

5.  Comparison between dexmedetomidine and remifentanil infusion in emergence agitation during recovery after nasal surgery: A randomized double-blind trial.

Authors:  R Polat; K Peker; I Baran; G Bumin Aydın; Ç Topçu Gülöksüz; A Dönmez
Journal:  Anaesthesist       Date:  2015-09-02       Impact factor: 1.041

6.  Review of the efficacy and safety of remifentanil for the prevention and treatment of pain during and after procedures and surgery.

Authors:  Erica L Sivak; Peter J Davis
Journal:  Local Reg Anesth       Date:  2010-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.